FDA Warns Online Sellers Over Compounded GLP-1 Marketing Claims
The U.S. Food and Drug Administration (FDA) has begun issuing warning letters to telehealth and online companies that are marketing compounded versions of glucagon-like peptide-1 (GLP-1) receptor agonists. These letters target companies making unsubstantiated claims about the efficacy and availability of these compounded drugs, which are often marketed for weight loss. The FDA’s action highlights […]